

**REMARKS**

The claims in this application have been amended, solely for the purpose of complying with U.S. claiming conventions.

Respectfully submitted,

KLARQUIST SPARKMAN CAMPBELL  
LEIGH & WHINSTON, LLP

By William D. Noonan  
William D. Noonan, M.D.  
Registration No. 30,878

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

09069664-101004  
T00T0T "49569350

**Marked-up Version of Amended Claims  
Pursuant to 37 C.F.R. §§ 1.121(b)-(c)**

**Claims**

8. (Amended) A delivery vehicle comprising the nucleic acid molecule according to [any of Claims 1-4] Claim 1 and/or the polypeptide according to Claim 7, which optionally is in the form of a suspension.

14. (Amended) A method for the treatment of orofacial clefting comprising administering to a patient suffering from orofacial clefting the nucleic acid molecule according to [any of Claims 1-4] Claim 1 and/or polypeptide of Claim 7.

15. (Amended) A method for the treatment of wounds and/or tissue repair comprising administering to a patient suffering from a wound and/or tissue damage the nucleic acid molecule [molecule] according to [any of Claims 1-4] Claim 1 and/or the polypeptide of Claim 7.

16. (Amended) A method of treatment [according to either Claim 14 or Claim 15 wherein said nucleic acid molecule and/or polypeptide is administered by the incorporation of said nucleic acid molecule into a delivery vehicle according to either of Claims 8 or 9] of wounds and/or tissue repair comprising administering to a patient suffering from a wound and/or tissue damage a composition comprising the delivery vehicle of Claim 8.

17. (Amended) A nucleic acid according to [any of Claims 1-4] Claim 1 and/or a protein according to Claim 7 for use as a pharmaceutical.

18. (Amended) Use of the nucleic acid according to [any of Claims 1-4] Claim 1 and/or [a] the protein according to Claim 7 for the manufacture of a medicament for the treatment of orofacial clefting and/or wound healing and/or tissue repair.

21. (Amended) A nucleic acid according to [either Claim 18 or] Claim 19 that is murine in origin.

23. (Amended) A delivery vehicle comprising the isolated nucleic acid molecule according to [any of Claims 19-21] Claim 20 and/or the polypeptide according to Claim 22.

26. (Amended) Use of antibodies according to [either of Claims 24 or 25] Claim 24 in diagnosing and/or detecting orofacial clefting.

29. (Amended) A method of producing a transgenic mammal according to [either of Claims 27 or 28] Claim 28 wherein the transgenic mammal is a mouse.

30. (Amended) A method of producing [a] the transgenic mammal according to [any of Claims 27-29] Claim 27 wherein the gene encoding the tissue repair protein is the nucleic acid molecule [according to any of Claims 19-21] comprising a nucleotide sequence which hybridizes to the nucleic acid of SEQ ID NO: 3 under high stringency conditions.

32. (Amended) A method of producing a transgenic mammal according to [either of Claims 27 or 31] Claim 27 wherein the gene encoding the tissue repair protein is [the] a nucleic acid molecule [according to any of Claims 1-4] which encodes a tissue repair protein and comprises a nucleotide sequence which hybridizes to the nucleic acid of SEQ ID NO: 1 under high stringency conditions.